Infant Refsum disease is a dubious disease in the field of genetic metabolism, clinical performance is complex and often involves multi-systematic stress. Early identification and normalisation of clinical care are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
The platform can help align teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of infant refsum disease requires individualized development of treatment programs, typically including drug therapy, rehabilitation interventions, regular follow-up, and other multidimensional management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many genetic metabolic diseases that were previously difficult to treat have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner according to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of infant refsum disease. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.